Rezolute, Inc.

NASDAQ:RZLT

Biotechnology

Healthcare
$4.25 +6.16%

+$0.30 today

Market cap
$411.10M
Beta
0.65
P/E (TTM)
-6.5
EPS (TTM)
-$0.78
52W Low $1.07High $11.46

Volume 2.93M

Average 2.03M

RZLT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Rezolute, Inc.NASDAQ: RZLT

Depreciation & Amortization · Q3 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $8K rose 14.3% year over year, ahead of the +3.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 14.3% from the prior quarter. Over 3 fiscal years it compounded at +33.6% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +14.3% holds above the trailing-twelve-month pace of +3.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8K+14.3% QoQ
Last fiscal yearJun 2025
$31K-13.9% YoY
LTMMar 2026
$31K+3.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.3%——
1 year-13.9%——
3-year CAGR+33.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
31K USD
Year-over-year change
-13.9%
4-year CAGR
+24.3%

Depreciation & Amortization vs competitors

How RZLT compares with its peers on the latest reported figures

  • RZLT's LTM Mar 2026 depreciation & amortization of $31K is the lowest of the 5 companies compared; the peer median is $7.26M.
  • Its year-over-year change of +3.3% is the highest of 5, against a peer median of -27.9%.
  • Over three fiscal years its annual growth of +33.6% compares with a peer median of +8.9%.
RZLT Competitors Peer median
Depreciation & Amortization for RZLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$34.01M -4.7%+24.3%5.1%
PHARPharming Group N.V.LTM Mar 2026$11.75M -9.8%-6.6%3.2%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$2.77M -57.2%+62.5%2.3%
RLYBRallybio CorporationLTM Mar 2026$67K -46.0%-18.0%7.8%
RZLTRezolute, Inc.LTM Mar 2026$31K +3.3%+33.6%—
Peer median (excluding RZLT) $7.26M-27.9%+8.9%4.1%

Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue00000
Cost of Revenue13K0000
Gross Profit(13K)0000
Gross Margin—————
Research & Development14.99M32.49M43.81M55.74M61.53M
Selling, General & Admin7.91M9.36M12.18M14.68M18.37M
Operating Expenses22.88M41.84M55.99M70.42M79.89M
Depreciation & Amortization13K13K30K36K31K
EBITDA(20.51M)(39.24M)(51.76M)(68.42M)(74.38M)
EBITDA Margin—————
Operating Income(22.89M)(41.84M)(55.99M)(70.42M)(79.89M)
Operating Margin—————
Interest Income63K80K4.21M4.87M5.48M
Interest Expense375K1.81M000
Other Income / Expenses1.99M783K4.2M1.96M5.48M
Income Before Tax(20.9M)(41.06M)(51.79M)(68.46M)(74.41M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(20.9M)(41.06M)(51.79M)(68.46M)(74.41M)
Net Margin—————
EPS (Basic)(2.72)(2.26)(1.01)(1.33)(0.98)
EPS (Diluted)(2.72)(2.32)(1.01)(1.33)(0.98)
Weighted Avg Shares7.67M18.2M51.19M51.47M76M
Weighted Avg Shares (Diluted)7.67M19.49M51.19M51.47M76M

Rezolute, Inc.

NASDAQ:RZLT

Intrinsic Alpha fair value

Locked

Current Price

$4.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.